Evidence map›Paper›PMID 34244184›Full record

ArticleBMJ case reports2021

Removal of a migrated dexamethasone implant (Ozurdex) from the anterior chamber using an intravenous cannula.

Jae Yee Ku, Karl Mercieca, Kenneth Yau

Open access · greenAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Jae Yee KuDepartment of Eye and Vision Science, University of Liverpool, Liverpool, UK jku@liverpool.ac.uk.ORCID http://orcid.org/0000-0002-5758-7346
Karl MerciecaDepartment of Glaucoma, Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Kenneth YauDepartment of Glaucoma, Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Manchester Royal Eye Hospital · GBUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ozurdex is a dexamethasone intravitreal implant used for the treatment of macular oedema. A rare but serious complication is the migration of the implant into the anterior chamber (AC) in eyes with absent or incomplete posterior capsules that may lead to corneal decompensation. We report the case of a 75-year-old woman who presented with a 1-day history of decreased vision in her left eye. She had a history of complicated cataract surgery and had received multiple Ozurdex implants for postoperative cystoid macular oedema in the same eye. She had significant left corneal decompensation and a mobile Ozurdex implant in the AC. We report a simple but novel surgical technique for removing an Ozurdex implant from the AC using an intravenous cannula (Venflon). This technique can also be applied to removing a fluocinolone acetonide (Iluvien) implant in similar situations.

Indexed as

Diabetic RetinopathyMacular EdemaAgedAnterior ChamberCannulaDexamethasoneDrug ImplantsFemaleFluocinolone AcetonideGlucocorticoidsHumansIntravitreal InjectionsDexamethasoneDrug ImplantsFluocinolone AcetonideGlucocorticoidsanterior chambereyemacularetinasurgery

Identifiers

PMID34244184
PMCPMC8273452
OpenAlexW3179972155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.